Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.46 |
| ▸ | CTSL | P07711 | 10/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2102815 | 0.90 | CTSS (0.45) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL697392 | 0.90 | CTSS (0.45) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL3075491 | 0.89 | CTSS (0.50) | CTSSCTSLCTSBCTSKAGTR2 | |
| SCHEMBL3718913 | 0.89 | CTSS (0.50) | CTSSCTSLCTSBCTSKAGTR2 | |
| SCHEMBL696405 | 0.80 | CTSS (0.46) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL697292 | 0.80 | CTSS (0.46) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL2105960 | 0.80 | CTSS (0.46) | CTSSCTSLCTSBCTSKKMT2A | |
| SCHEMBL2104268 | 0.77 | CTSS (0.42) | CTSSCTSLCTSBCTSKEPHX2 | |
| SCHEMBL695511 | 0.77 | CTSS (0.42) | CTSSCTSLCTSBCTSKEPHX2 | |
| SCHEMBL2104430 | 0.77 | CTSS (0.54) | CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CTSS 1542/4885CTSL 178/4885CTSB 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.